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ABSTRACT 
Broad spectrum antimicrobial activity against biodefense pathogens is highly desirable as 
a delay in treatment of infection with these pathogens can be fatal. Engineered cationic 
antimicrobial peptides (eCAPs) are de novo synthesized amphipathic agents with broad spectrum 
activities against gram-positive and gram-negative bacteria including Pseudomonas aeruginosa 
and methicillin-resistant Staphylococcus aureus (MRSA).  We evaluated eCAPs designated as 
WLBU2 and WR12 against three bacterial pathogens that are considered potential biological 
weapons and a great public health concern. Using both bacterial killing and growth inhibition 
assays, different concentrations of WLBU2 and WR12 were tested in vitro against Francisella 
tularensis, Burkholderia pseudomallei, and Yersinia pestis. LL37, a natural mammalian 
antimicrobial peptide was used for comparison.  WLBU2 proved to be the best candidate against 
F. tularensis with a single dose of 3μM needed to achieve a 90% reduction in bacterial count and 
a minimum inhibitory concentration (MIC) of 25 μM. LL37 failed to achieve more than 8% 
reduction in the bacterial count of F. tularensis with concentrations up to 100 µM. Both WLBU2 
and WR12 achieved significantly better results against Y. pestis compared to LL37, but only WR12 
was able to attain a MBC of 50 μM. Results for B. pseudomallei varied depending on the testing 
environment; a substantial reduction in bacterial count was seen with WLBU2 in potassium 
phosphate buffer but not in phosphate buffered saline. WLBU3 and WLBU4 were also tested 
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against B. pseudomallei and results indicate that increasing the length of the peptides did not 
enhance their activity against B. pseudomallei. Moreover, WLBU2 was tested against Francisella 
tularensis (SchuS4) infected macrophage cells (J774) and found to decrease intracellular bacterial 
count by more than 90% at a concentration of 12.5µM. This data demonstrates the potential 
usefulness of eCAPs against the three pathogens that were evaluated and the broad applicability 
of eCAPs, particularly WLBU2, against bacterial biodefense pathogens. 
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PREFACE 
 
First, have a definite, clear practical ideal; a goal, 
an objective.  
Second, have the necessary means to achieve your 
ends; wisdom, money, materials, and methods.  
Third, adjust all your means to that end. 
– Aristotle 
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1.0 INTRODUCTION 
Biodefense agents are pathogenic organisms or toxins that pose a severe threat to public 
health and can be used against humans, animals, or plants for terrorist purposes. These agents are 
typically found in nature, but they could be also modified to enhance their virulence, ability to 
disseminate or make them resistant to current antibiotics or vaccines. Such biological agents are 
attractive to terrorists as an alternative to conventional weapons due to their low costs, their relative 
ease of production, ability to aerosolize, and difficulty of detection. Biodefense agents are 
classified by the National Institute of Allergy and Infectious Diseases (NIAID) according to the 
risk for human health into 3 categories of A, B and C [1]. In 2012, a new designation, "Tier 1", 
has been developed for those select agents and toxins considered to be of the greatest risk for 
deliberate misuse and the most significant potential for mass casualties or devastating effects on 
the economy or critical infrastructure [2]. 
Francisella tularensis, Burkholderia pseudomallei and Yersinia pestis are all gram 
negative facultative intracellular tier 1 select agents that are able to cause fatal diseases if not 
treated appropriately. The use or even threatened use of such organism can produce a widespread 
social disruption. Therefore, establishing effective treatment strategies against such pathogens is 
of the utmost importance. Unfortunately, some of these agents have already developed resistance 
against current available antibiotics emphasizing the need for new therapeutic agents [3][4]. In this 
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study, de novo engineered cationic antimicrobial peptides, WLBU & WR12, are investigated as a 
potential alternative for treatment of these organisms.  
 
1.1 Francisella tularensis  
Francisella tularensis is a small, pleomorphic, gram-negative coccobacillus and the 
causative agent of the bacterial zoonotic disease, tularemia [5]. F. tularensis was first isolated by 
McCoy in 1912 following an outbreak of a plague-like disease in rodents in Tulare County, 
California [6]. Since then four different subspecies of F. tularensis have been identified: tularensis, 
holarctica, mediasiatica and novicida [7]. Most human cases are caused by either subspecies 
holarctica or tularensis, with the latter being the more pathogenic subspecies. With the exception 
of a presumptive laboratory release, subspecies tularensis is only found in North America.  
Since its identification, tularemia cases have been documented throughout the Northern 
hemisphere including Europe, China, Korea, Japan, the former Soviet Union and North America. 
Up until the 1950s, the United States had thousands of tularemia cases reported annually with a 
peak number of 2,291 in 1939 [8]. With the discovery of antibiotics these numbers declined 
drastically reaching less than 150 cases per year between 1990 and 2000. Except for Hawaii, all 
American states have reported at least one case of tularemia with the majority of them residing in 
the south-central  and western region (Arkansas, Missouri, South Dakota, and Oklahoma) [9].  
Francisella tularensis is thought to be maintained in soil, water and through its extensive 
host distribution including humans, domesticated and wild animals such as lagomorphs, 
carnivores, rodents, birds and fish [10, 11]. It is primarily transmitted to humans and other animals 
through arthropod vectors such as biting flies and ticks. Ninety percent of tularemia cases in the 
United States occur via an arthropod bite, more specifically via the American dog tick, the Lone 
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Star tick, and the Rocky Mountain wood tick [10, 12]. It can also occur directly through 
contaminated food, water, infected animals and their carcasses [13]. Aerosolization of F. tularensis 
can occur during handling of contaminated material which may lead to the inhalation of the 
bacteria. For instance, 11 cases of primary pneumonic tularemia occurred in the summer of 2000 
on Martha’s Vineyard Massachusetts due to the aerosolization of the bacteria from infected animal 
carcasses and their dens during lawn mowing [14].  Further, laboratory transmission of F. 
tularensis can occur readily due to the ease of its aerosolization; opening a culture plate is enough 
to create an aerosol  [15]. To date, there has been no supportive evidence of person to person 
transmission.   
The onset of tularemia is usually abrupt with flu-like symptoms, fever and generalized 
weakness. Chest tightness, sub-sternal pain and dry cough have also been noted [16]. Following 
an incubation period between 1 to 21 days and depending on the route of inoculation, tularemia 
manifests in one of six forms: oropharyngeal, pneumonic, typhoidal, ulceroglandular, glandular or 
oculoglandular [17].  The most common form of the disease is ulceroglandular tularemia following 
an infected arthropod bite or handling contaminated  animals [18]. Pneumonic tularemia results 
from inhaling contaminated aerosols or through the dissemination of the bacteria from another site. 
It is characterized by an acute illness with pharyngitis, pleuropneumonitis, bronchiolitis and/or 
hilar lymphadenitis [19].  Patients may progress into respiratory failure and death. Typhoidal 
tularemia has no specific site of inoculation and is characterized with systemic illness including 
fever, abdominal pain, and diarrhea and vomiting. If not treated promptly, both typhoidal and 
pneumonic tularemia may lead to death [13]. 
In situations of contained tularemia causalities, where individual patient management is 
possible, a parenteral route of treatment with antibiotics is recommended. The aminoglycosides 
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streptomycin and gentamicin are both bactericidal against F. tularensis and are considered the gold 
standard for treatment in these situations. Streptomycin (1 g IM twice daily) or gentamicin (5 
mg/kg IM or IV once daily) should be continued for 10 days.  Tetracycline or chloramphenicol are 
bacteriostatic against F. tularensis and can be used as alternative treatment. Due to their 
bacteriostatic profile, these drugs should be continued up to 14 days to reduce the possibility of 
relapse [13](23).  
Fluoroquinolones, such as ciprofloxacin and doxycycline, have a bactericidal effect against 
intracellular organisms such as F. tularensis. During a human outbreak in Spain (between 
December 1997 and February 1998) ciprofloxacin treatment resulted in the lowest therapeutic 
failure and side effects compared to streptomycin and doxycycline [20]. Currently, ciprofloxacin 
can be regarded as the drug of choice for the treatment of uncomplicated tularemia and as a second-
line treatment for severe infections; although relapse may occur due to incomplete clearance of F. 
tularensis. In case of massive causalities, e.g. during a bioterrorism attack, oral doxycycline and 
ciprofloxacin are the preferred choices for both adults and children. Achieving the appropriate 
treatment decreases the mortality rate of tularemia from 35%  to 1% [21]. Post-exposure 
prophylactic treatment would include streptomycin, gentamicin, doxycycline, or ciprofloxacin for 
14 days [13]. Even with antibiotics available for treatment of F. tularensis infection, pneumonic 
tularemia requires intensive care and the recovery rate is extremely slow so that even a moderate 
outbreak can overwhelm medical facilities. Further, F. tularensis can be genetically modified to 
become antibiotic resistant.  
The F. tularensis live vaccine strain (LVS) is the only vaccine available to protect against 
tularemia. LVS was generated in the former Soviet Union as a classically passaged live attenuated 
strain derived from a virulent F. tularensis subsp. holarctica strain. Studies conducted in the 
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1960’s demonstrated that LVS was safe when given to humans and could protect against aerosol 
challenge with SchuS4, a virulent strain of F. tularensis subsp. tularensis although this protection 
failed at higher challenge doses. Nevertheless, LVS is only available as an Investigational New 
Drug (IND) and unlikely to be approved by the FDA due to concerns regarding the potential for 
reversion and incomplete protection against aerosolized F. tularensis. As an IND, LVS is currently 
given to at-risk laboratory personnel who work with tularemia. Consequently, there is no actual 
way of controlling this disease in nature. Public awareness of this organism and its potential harm 
to humans should be a priority. In regions where tularemia is endemic, people should avoid 
handling sick or dead animals and insect populations should be reduced [22].  
F. tularensis is considered one of the most infectious bacterial pathogens. In a bioterrorist 
attack F. tularensis would most likely be used as an aerosol resulting in pneumonic tularemia 
represented as respiratory symptoms, sub-sternal discomfort, and cough. In 1970, a World Health 
Organization (WHO) committee stated that a 50-kg aerosol dispersion of a virulent F. tularensis 
strain in a population area of five million people would cause 19,000 deaths and 250,000 
hospitalizations. Without the appropriate antibiotics, most of the hospitalized cases would progress 
into respiratory failure and death [23]. F. tularensis progression is slower than anthrax or plague, 
but the disease caused by this organism persists for several weeks with a high relapse rate.  The 
WHO estimated that such an attack with tularemia would cost around $5.4 billion per 100,000 
persons infected [24].  
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1.2 Burkholderia pseudomallei  
Burkholderia pseudomallei is a gram-negative, motile rod-shaped, soil saprophyte that can 
be easily collected from water and wet soil in endemic areas.  B. pseudomallei is the causative 
agent of melioidosis, a tropical infectious disease affecting humans, animals and plants. Previously 
known as Pseudomonas pseudomallei, B. pseudomallei is able to infect various organs causing a 
range of clinical symptoms that might be fatal to the infected patient. Despite its rare presence in 
the western countries, concern about the potential use of B. pseudomallei in bioterrorism fuels a 
great deal of the B. pseudomallei research. 
Melioidosis is endemic in various areas of Southeast Asian and northern Australia.   
Thailand has the highest annual incidence of melioidosis; 4.4 cases per 100,000. In Ubon 
Ratchathani – Thailand, 20% of community acquired bacterial infections are due to B. 
pseudomallei [25]. Further, severe melioidosis has a case fatality rate of 50% in that region [26]. 
Northern Australia has about the same incidence rate as Thailand, and B. pseudomallei is 
considered the most common case for fatal community acquired bacterial pneumonia; the mortality 
rate is about 20% among patients with melioidosis [27]. Sporadic cases were observed worldwide, 
particularly in the Caribbean region, Africa and the Middle East [28]. Cases that occurred in the 
western countries usually involved returning travelers and military veterans [29].  
Humans and animals can be infected through ingestion, inhalation or inoculation of a skin 
wound. In humans, most cases occur directly from the environment through skin abrasions. 
Inhalation of B. pseudomallei is usually related to heavy rainfalls and strong wind that might carry 
it from the soil or water into our respiratory system [30]. Person to person transmission is rare, but 
has been reported between family members in close contact [31]. Vertical transmission is also 
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considered rare with only a few newborn cases reported [32]. Transmission by mosquitoes and rat 
fleas has been reported, but the role of vector born transmission remains unclear [28, 33].   
Melioidosis is often referred to as “the great imitator” due to its wide spectrum of clinical 
diseases. Melioidosis can present as an acute or chronic, localized or generalized disease. Other 
cases may result in an inapparent infection with no noticeable signs or symptoms [34]. Following 
an incubation period between 1 and 21 days, the lung is mostly affected by this organism. The 
ensuing pulmonary disease can range from mild respiratory illness to acute or chronic pneumonia 
that may rapidly progress to septic shock and death. Pneumonia is the most common manifestation 
between all patients with melioidosis [25] and may progress to septicemia if left untreated. 
Septicemic melioidosis is the most serious form of the disease with a mortality rate as high as 70%  
[35][36].    
Despite being intrinsically resistant to many drugs, B. pseudomallei is susceptible to some 
antibiotics. Treatment is divided into 2 phases: intensive and eradication. As a general rule, 
intravenous bactericidal drugs are used in the intensive phase, while oral bacteriostatic drugs are 
used in the eradication phase. In life threatening disease, the current regimen is comprised of 
intravenous Ceftazidime for at least 2 weeks followed by oral combination of ciprofloxacin and 
azithromycin or doxycycline and co-trimoxazole for 20 weeks to prevent relapse.  For mild to 
moderate disease, IV amoxycillin-clavulanate is used for 2 weeks followed by co-trimoxazole and 
doxycycline for 20 weeks. Localized melioidosis should be treated with incision and drainage with 
co- trimoxazole for 6 – 8 weeks [37].   
Relapse and recurrence of infection is common in melioidosis despite receiving appropriate 
therapy. Relapse is defined as “reappearance of signs and symptoms after clinical response while 
still on antimicrobial therapy” while recurrent infection is “a new episode of melioidosis caused 
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by the same organism after full clinical recovery” [38]. Both infections are thought to be due to 
failure of the host to eliminate the offending pathogen during initial attack. Many factors aid B. 
pseudomallei evasion of the host system including hiding in phagocytic cells and sealed abscesses. 
In endemic areas such as Malaysia and northeast Thailand the overall relapse rate is higher than 
15% per year despite prolonged treatment [39].  
With no effective vaccine available, precautionary measures should be taken in endemic 
areas. These measures include covering all open wounds and wearing the appropriate gear for 
outdoor activities. Infected animals are usually euthanized rather than treated due to the high risk 
of relapse and expensive medication needed. If treated, animals should be under lifelong 
monitoring for relapse [38]. 
CDC assigned B. pseudomallei as a category B select agent and a possible bioweapon 
leading to an increased research interest around the world. Even in literature, this agent’s potential 
as a bioweapon was suggested by Sir Arthur Conan-Doyle in his Sherlock Holmes story “The 
Dying Detective” [40]. It is believed that B. pseudomallei was being weaponized by the former 
USSR with the potential of creating an engineered antibiotic resistant strain. Although the 
prospective of weaponizing this agent is uncertain, it has a great potential due to its high mortality 
rates, wide range of hosts, ability to be aerosolized and intrinsic antibiotic resistance 
 
1.3 Yersinia pestis   
Yersinia pestis is a gram-negative, non-motile, non-spore forming coccobacillus belonging 
to the family Enterobacteriaceae. Y. pestis is believed to be a clone of Y. pseudotuberculosis that 
emerged within the last 1,500 to 20,000 years by acquiring different genetic elements making it 
able to be transmitted through fleas [41]. Y. pestis had numerous nomenclature changes from 
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Bacterium pestis to Bacillus pestis to Pasteurella pestis and finally Y. pestis in 1970 [42]. Plague 
(a.k.a the Black Death) is the zoonotic disease caused by this organism. It can be transmitted to 
humans through flea bites causing a rapidly progressive severe illness that is usually deadly if not 
appropriately treated.  
Plague was the cause of three major pandemics in which nearly 200 million people were 
killed. The first pandemic, the Justinian plague, started in Egypt around A.D. 541 and then swiftly 
transmitted through the Middle East and Mediterranean Europe leading to the loss of 50 – 60% of 
the population. The second pandemic started with an epidemic in Europe during the 14th century. 
This epidemic killed 17 to 28 million Europeans (30 – 40% of the population) and more 
importantly resulted in relentless epidemic cycles that comprise the second pandemic.  The third 
pandemic started in China around 1855 and disseminated to Africa, Australia, Europe, Middle 
East, North America, and South America by 1900. It is believed that plague was introduced to the 
United States from China in the 20th through ship rats and their fleas. Fortunately, mortality rates 
were significantly reduced compared to previous pandemics which is thought to be due to effective 
antibiotics and active public health measures [43]. Currently, it is believed that around 4,000 
human plague cases occur annually worldwide [44].   
Plague is enzootic in rodents, but it can be transmitted to humans by infected fleas. When 
the rat fleas, the classical vector for plague, feed on an infected animal the bacteria infects and 
multiplies in the midgut of the flea. Ultimately the flea dies out of starvation, but not before 
infecting several hosts. In the infected mammal, Y. pestis spreads from the bite site to the regional 
lymph node and multiply quickly causing the lymph node to swell and form a bubo. Further, the 
bacteria spread to the bloodstream and colonize in different organs such as liver, spleen and lung 
[45].  
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Y. pestis can rarely transmit to humans through direct contact with infected animals 
especially rodents. Person-to-person transmission through respiratory droplets may occur; in 1994 
an outbreak of pneumonic plague occurred in Surat, India. A total of 460 plague cases were 
compiled between September 20 and September 25 in Surat. When news of the plague became 
known to the public about 700,000 people fled the city.  It is estimated that this small outbreak 
cost India US$3 billion and the global economy US$5 to $6 billion [46]. Fortunately pneumonic 
plague is rare, but bubonic plague may spread to the lungs triggering a secondary pneumonic 
plague that can be transmitted to other people and cause considerable mortality if untreated [43].  
Plague manifests as one of three primary forms: Bubonic, septicemic, or pneumonic. 
Human epidemics commonly start as bubonic plague following a flea’s bite. If not treated promptly 
infected patients usually develop secondary plague septicemia or pneumonia increasing the risk of 
person to person transmission. Untreated bubonic plague may lead to 40 – 60% case fatalities 
while untreated septicemic and pneumonic plague is always fatal; death is usually due to a septic 
shock [47, 48].  
Pneumonic plague is very rare, nonetheless it is the most dangerous and deadly form of the 
disease. Disease spreads via respiratory droplets from infected animals or humans. It initially 
presents as a febrile like illness but progresses rapidly with 1 to 3 days into an overwhelming 
pneumonia with productive bloody cough, dyspnea and cyanosis.  Cervical lymph nodes may be 
affected creating buboes in the neck region. The disease quickly overwhelms the lungs and 
hemorrhages develop resulting in hemorrhagic pneumonia. The terminal events may include 
respiratory failure and circulatory collapse. Septicemic plague patients may develop secondary 
plague pneumonia through the hematogenous dissemination of the bacteria to the lung (68)[49]. 
11 
 
Rapid diagnosis and prompt administration of appropriate antibiotics are essential for the 
success of treatment and reduction of complications. Streptomycin, tetracycline, and sulfonamides 
are considered the standard treatment, with streptomycin being the treatment of choice for plague. 
Using one or a combination of antibiotics depends on the severity of the infection.  Gentamicin 
alone or with tetracycline can be used as a substitute for streptomycin. Antibiotic treatment 
continues for 10 days or 2 days after the fever subsides. Patients suspected of having pneumonic 
plague or secondary pneumonia following bubonic plague should be isolated for at least 4 days 
after starting treatment to prevent human-to-human transmission [50, 51].  A recent study by 
Layton et al demonstrated successful treatment of established pneumonic plague using 
Levofloxacin in African green monkeys. The monkeys were given a respiratory dose of 100 lethal 
doses for 50% of animals (LD50) and were observed for fever and vital signs by telemetry. 
Intravenous Levofloxacin treatment was initiated when the animal spiked a fever in a fashion that 
mimics antibiotic levels achieved in humans. All animals treated with a placebo died, while all 
animals treated for 10 days with Levofloxacin survived. In the treated group fever resolved within 
24–48 hours of initiating treatment. This study indicates that Levofloxacin may be a suitable broad-
spectrum antibiotic for therapy in an aerosolized bioweapons attack and should be further studied 
and evaluated for bubonic plague [52]. 
Prophylactic therapy consists of sulfonamide, trimethoprim-sulfamethoxazole, or 
tetracycline administered to the patient and their close contacts.  In the case of a bioterrorist attack 
with aerosolized plague, streptomycin or gentamicin are the preferred choice in a contained 
casualty setting, while oral therapy with doxycycline, tetracycline, Levofloxacin or ciprofloxacin 
are preferred for mass casualty situations. There are two plague vaccines currently available 
around the world: a live vaccine made from an attenuated strain of Y. pestis and a killed vaccine 
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derived from a formalin-fixed virulent strain. Vaccines are administered intramuscularly as a series 
of three primary shots over a period of a year then booster shots should be given every 1 to 2 years. 
Due to their side effects, need for repeated boosters and ineffectiveness against pneumonic plague, 
these vaccines are  only given to people at high risk of contracting Y. pestis such as military 
personnel serving in endemic areas [53, 54].   
In 1995, two multi-drug resistant isolates of Y. pestis were observed in Madagascar. One 
strain was isolated from a 16 year old male and the other from a 14 year old patient with both of 
them presenting symptoms of bubonic plague. Both strains were resistant to streptomycin and 
several other antibiotics recommended for plague treatment. Both patients were successfully 
treated with a combination of intramuscular injections of streptomycin (2 g per day for 4 days) and 
oral administration of trimethoprim-sulfamethoxazole (2 g per day for 10 days) [50]. Thus there is 
cause for concern that antibiotic resistant strains of Y. pestis could occur naturally or be made in a 
laboratory. 
Due to its high fatality and rapid progression, Y. pestis is considered a potential biological 
weapon. During the World War II, the Japanese army released plague-infected fleas over several 
areas in China leading to many plague outbreaks [55]. Offensive biological weapons programs in 
both the USA and the Soviet Union researched and successfully developed techniques to aerosolize 
plague in place of using infected fleas. It was estimated by the WHO that releasing an aerosol of 
50kg of Y. pestis over a city of 5 million would lead to development of pneumonic plague in 
150,000 people, of which 36,000 are expected to die [56]. Research in weaponizing Y. pestis was 
terminated in the USA around 1970 (when all offensive biological warfare research was 
terminated) but it continued in the Soviet Union. In the year 1995 an individual in Ohio was 
arrested after illegally acquiring Y. pestis by mail. This incident lead to establishment of new 
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antiterrorism regulations which included regulations guiding tracking shipments (and eventually 
inventories) of pathogens designated as ‘select agents’, those for which there was concern they 
could be used as biological weapons. Today Y. pestis is classified as a tier 1 select agent by the 
United States Department of Health and Human Services [57].  
 
1.4 Engineered Cationic Antimicrobial Peptides (eCAPs) 
Cationic antimicrobial peptides (CAPs) are amphipathic peptides of 12–50 amino acids 
with a net positive charge. They are ubiquitous peptides naturally found in all living species and 
are known to be active components of the innate immunity against infectious pathogens [58]. In 
response to infectious pathogens, CAPs can be released from macrophages, granules of 
neutrophils, or with mucosal and skin secretions from epithelial cells. CAPs can act against a wide 
range of targets including gram-positive and gram-negative bacteria, fungi and parasites - the only 
essential component in these targets is a negatively charged plasma membrane. Therefore, normal 
cells have a relative resistance due to the peptides preference for negatively charged, cholesterol 
free membranes [59]. The mechanism of action of CAPs is not fully understood, although studies 
have implicated the electrostatic interaction between the peptides and the lipid molecules on the 
bacterial membrane. When compared to other antibiotics, CAPs are able to kill bacteria rapidly, 
within 30 to 180 seconds, limiting the bacterium’s ability to develop resistance against these 
peptides. Therefore, CAPs are considered a good candidate for use against multi-drug resistance 
(MDR) bacteria. 
Although these cationic peptides have a wide spectrum of action against pathogens, their 
activity strongly depends on the environment they are released in. The optimal potency of each 
peptide is only achieved in specific environmental conditions and readily lost when subjected to a 
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different setting. For instance, human β-defensin loses its antimicrobial activity when subjected to 
the abnormally high NaCl concentration in a cystic fibrosis lung [60]. Therefore, to be able to 
utilize their antimicrobial activity to the fullest, development of CAPs has shifted towards 
modifying host-derived peptides or choosing specific amino acids for de novo synthesis. Studies 
of an HIV-1 transmembrane protein (referred to as lentivirus lytic peptide 1 (LLP1)) demonstrated 
that it had remarkable antimicrobial properties [61]. As a result of that work, it was concluded that 
de novo synthesis of an α-helical amphipathic cationic antimicrobial peptide, using arginine 
residues on the polar side and valine residues on the non-polar side, would greatly improve the 
potency and selectivity of the peptide [62]. Further studies of the influence of length and helical 
structure on activity lead to development of a series of de novo synthesized peptide designated 
WLBU [63]. WLBU peptides are composed of arginine in the hydrophilic face, valine and 
tryptophan residues in the hydrophobic face separated from each other by at least seven amino 
acids (Figure 1). Moreover, WLBU studies demonstrated that tryptophan substitution significantly 
increased antimicrobial activity in challenging environments such as serum and blood. Therefore, 
WR12 was designed using only arginine in the hydrophilic face and tryptophan in the hydrophobic 
face [63, 64] (Figure 1).  
Several studies tested the potency of engineered peptide derivatives against various agents 
such as Pseudomonas aeruginosa, methicillin resistant Staphylococcus aureus, Streptococcus 
gordonii, Fusobacterium nucleatum, and Porphyromonas gingivalis [65-68]. Unlike the natural 
peptide LL37, WLBU2 was able to eliminate P. aeruginosa and S. aureus in physiological NaCL 
concentrations and kill P. aeruginosa in human serum, whole blood and skin fibroblasts without 
evident adverse effects to the host cells. In vivo toxicity and efficacy of WLBU2 against P. 
aeruginosa were also tested using a mouse model. An intravenous dose of 3mg/kg of WLBU2 was 
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able to clear the bacteria and save all the 14 mice from the P. aeruginosa infection. WLBU2 had 
no apparent toxic effect on the mice at up to 12 mg per kg of their body weight [64]. Further, 
WR12 and WLBU2 demonstrated an optimal antibacterial selectivity against a panel of MDR 
clinical isolates such as Acinetobacter baumannii and Klebsiella pneumoniae [66]. Taking all this 
into consideration, this study aims to evaluate the in vitro and ex vivo antimicrobial activity of 
WLBU series and WR12 against F. tularensis, B. pseudomallei and Y. pestis.   
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 2.0 SPECIFIC AIMS 
This study aims to investigate the potential role of WLBU and WR12 as a antimicrobial 
agents against F. tularensis, B. pseudomallei and Y. pestis. The potency of WLBU and WR12 is 
compared to that of LL37 under defined test condition to demonstrate the ability of de novo 
synthesized peptides with optimized amphipathic structures to overcome certain limitations of host 
antimicrobial.  
 
2.1  AIM 1: Evaluate the antimicrobial activity of WLBU and WR12 in vitro against virulent 
isolates of all three bacterial pathogens (F.tularensis, B. pseudomallei, and Y. pestis) to 
establish their ability to kill or inhibit growth of the pathogens. All procedures will be first 
evaluated with the attenuated LVS strain of F. tularensis prior to use in BSL-3. 
 
a. Determine the growth of each pathogen in specified media and the exponential phase by 
establishing a growth curve for each of them. This will further help in determining the 
equations needed for bacterial concentration calculations.  
 
b. Determine the effectiveness of our peptides in reducing the bacterial count of the tested 
pathogens and the minimum bactericidal concentration (MBC), if applicable. 
 
 
c. Determine the effectiveness of our peptides in inhibiting the growth of the tested pathogens 
and the minimum inhibitory concentration (MIC), if applicable.    
 
 
2.2  AIM 2: Assess the antimicrobial activity of WLBU2 ex vivo with F. tularensis infected 
macrophages. 
 
a. Determine ability of WLBU2 to modulate macrophage cells (J774) cell viability. 
 
b. Determine the reduction in bacterial counts after using WLBU2 against F. tularensis 
(SchuS4) infected J774 cells.  
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3.0 METHODS AND MATERIALS 
3.1 Biosafety  
All experiments using F. tularensis, B. pseudomallei or Y. pestis were performed in the 
biosafety level 3+ Regional Biocontainment Laboratory (RBL) at the University of Pittsburgh.  
Powered air purifying respirators (PAPRs) were worn for respiratory protection, and all work 
was conducted in a class II biosafety cabinet using Vesphene IIse (diluted 1:128, Steris 
Corporation, cat. #646101) as a disinfectant.   
 
3.2 Bacteria 
All the following bacteria were obtained from Biodefense and Emerging Infections 
Research Resources Repository, Manassas, VA. Francisella tularensis live attenuated vaccine 
strain (LVS) and SchuS4 strain (Catalog No. NR-643) were grown on cysteine heart agar (CHA) 
for 2 days at 37°C  and cultured in brain heart infusion broth (BHI) or Chamberlain’s chemically 
defined medium (CCDM) for 17 to 19 hours  [69]. Burkholderia pseudomallei strain 1026b 
(Catalog No. NR-9910) was grown on Luria Broth (LB) Agar for one day at 37°C and then cultured 
in BHI for 11 hours. Yersinia pestis strain CO92 (Catalog No. NR-641) was grown on tryptic soy 
agar (TSA) for 2 days at 37°C and then cultured in BHI or Bacto nutrient broth for 24 to 27 hours. 
The overnight culture of bacteria was prepared by streaking an agar plate with a loopful of the 
frozen bacterial stock (-80 freezer). The plate was incubate for 24hrs at 37°C for B. pseudomallei, 
48 hrs at 37°C for F. tularensis and 48hrs at   30°C for Y. pestis. Next, several colonies were taken 
from the plate and re-suspend in 3ml of growth media e.g. BHI. Optical density (OD) was adjusted 
to 0.1 then 0.5ml of the previous solution was added to 24.5ml of the growth media in a 125ml 
18 
 
filtered top flask. Bacterial culture was incubated at 37°C in a shacking incubator (250 rpm) for 
the number of hours needed for the bacteria to reach the exponential phase; B. pseudomallei 
(11hours), Y. pestis (24 – 27 hours), and F. tularensis (17 – 19 hours). After incubation, 10ml of 
the culture were spun down at 2800 rpm for 10 minutes then re-suspend in PBS or Growth media 
depending on the assay done.  
 
3.3 Peptides 
Peptides were synthesized using standard Fmoc (9-fluorenylmethoxycarbonyl chloride) 
synthesis protocols (Genscript, Piscataway, NJ). Synthetic peptides were characterized and 
purified by reverse-phase high pressure liquid chromatography on Vydac C18 or C4 columns (The 
Separations Group, Hesperia, Cal.). The identification of each was established by mass 
spectrometry (Electrospray Quatro II triple quadruple mass spectrometer; Mi-cromass, Inc., 
Manchester, United Kingdom). Peptide concentrations were determined using a quantitative 
ninhydrin assay. The peptides and their sequences were as follows. 
 
WLBU2: 24-mer peptide composed of 13 arginine (R) in the hydrophilic face and 8 valine 
(V) and 3 tryptophan (W) residues in the hydrophobic (Figure 1)  
(RRWVR RVRRV WRRVV RVVRR WVRR) 
 
WLBU3: 36-mer peptide composed of 18 arginine in the hydrophilic face and 14 valine 
and 4 tryptophan residues in the hydrophobic 
(VRRVW RRVVR VVRR WVRR VRRV WRRV VRVV RRWVRR) 
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WLBU4: 48-mer peptide composed of 23 arginine in the hydrophilic face and 20 valine 
and 5 tryptophan residues in the hydrophobic 
(RVVRV VRRWV RRVRR VWRRV VRVVR RWVRR VRRVW RRVVR 
VVRRW RVV) 
 
WR12: 12-mer peptide composed of 6 arginine in the hydrophilic face and 6 tryptophan 
residues in the hydrophobic; requires mannitol to prevent precipitation (Figure 1) 
(RWWRWW RRWWRR) 
 
LL37: 37-mer peptide (Leu,Gly,Asp,Phe,Arg,Lys,Ser,Glu,Ile,Val,Gln,Pro,Thr); first 
natural amphipathic alpha helical peptide isolated from human 
( Leu - Leu - Gly - Asp - Phe - Phe - Arg - Lys - Ser - Lys - Glu - Lys - Ile - Gly - Lys - 
Glu - Phe - Lys - Arg - Ile - Val - Gln - Arg - Ile - Lys - Asp - Phe - Leu - Arg - Asn - Leu 
- Val - Pro - Arg - Thr - Glu – Ser) 
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3.4 Assays 
 
3.4.1 In vitro assays:  
Prior to any experiments, growth curves were established for each pathogen to determine 
log-phase and stationary phase. Also, mathematical equations were derived from calibration curves 
(optical density/colony-forming unit (c.f.u) curves) to achieve the needed bacterial concentration.  
 
Bacterial killing assay (BKA): A of bacterial suspensions (concentration of 1×106 c.f.u/mL) in 
phosphate buffer saline or potassium phosphate buffer were incubated with two-fold dilutions of 
peptides (concentration of 1.5µM to 100µM) in a 96-well plate (Falcon No. 3072, Becton-
Dickinson, Oxnard, CA) for 60 min at 37°C.  Serial peptide dilutions were performed and plated 
on agar plates. Colonies were counted following an appropriate incubation time to determine the 
reduction in bacterial count. The minimum bactericidal concentration (MBC) is determined as 
peptide concentration reducing bacterial count by at least 99%.  
 
Growth inhibition assay (GIA): Bacterial suspensions (concentration of 1×106 c.f.u/mL) in growth 
media were incubated with two-fold dilutions of peptides (concentration of 1.5µM to 100µM) in 
a 96 well plate for 24 to 48 hours at 37°C.  After incubation the optical density of each well was 
measured at 600nm using a spectrophotometer. Percent inhibition was calculated from the 
difference in optical density measured. The minimum inhibitory concentration (MIC) was 
determined as peptide concentration reducing bacterial growth by at least 90%.  
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3.4.2 MTS assay: 
Macrophage J774 cells (ATCC TIB – 67) were seeded in Dulbecco's Modification of 
Eagle's Medium (DMEM, Cellgro) supplemented with 10% fetal bovine serum at 37°C on 96-
well cell culture plates at a density of 3 × 108 cells/well. A set of wells is prepared with medium 
only for background subtraction and another with untreated cells for 100% viability reference. 
Seeded Plate was incubated overnight at 37 °C, 5% CO2, 95% humidity. WLBU2 was added at 
concentration ranging from 3 µM to 100 µM and incubated for an hour. Following incubation 
cells were washed using PBS and 100 µL of media were added to each well. Then 20 µl of MTS 
solution, 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (Sigma, Lakehood, N.J.), were added to each well (final concentration of MTS will 
be 0.33 mg/ml) and incubated for 2hr at 37°C. Absorbance was recorded at 490 nm to determine 
the viability of cells with different peptide concentrations compared to untreated cells.  
 
3.4.3 Ex vivo assay: 
For ex vivo infection with F. tularensis, a standardized assay using a mouse macrophage 
cell line (J774) was used. J774 cells were seeded in Dulbecco's Modification of Eagle's Medium 
(DMEM, Cellgro) supplemented with 10% fetal bovine serum at 37°C on 12-well cell culture 
plates at a density of 3 × 107 cells/well. Seeded plates were incubated overnight at 37 °C, 5% CO2, 
95% humidity. Cells were infected with F. tularensis SchuS4 at an MOI of 1:100 and incubated 
further for 2 hr. Cells were washed three times with 2 ml of potassium buffer saline(PBS) 
containing 50µg/ml gentamicin followed by addition of 1ml of media with 50µg/ml gentamicin to 
each well  and incubated for 1 hr. Subsequently, cells were washed again three times with PBS 
and different concentrations of WLBU2 (3µM to 25µM) was added to each well and incubated for 
22 
another 1hr. Cells  were then lysed using 0.02% sodium dodecyl sulfate (SDS) and 100µl of the 
lysate was further diluted in PBS and plated on CHA. Colonies were counted to determine bacterial 
count reduction with WLBU2. 
3.5 Statistical Analysis: 
Analysis was performed using percentages. Significance of differences in bacterial killing 
or inhibition between different peptides was conducted using two way analysis of variance 
(ANOVA) in Graphpad prism 6. P < 0.0001 was considered to be statistically significant. 
WLBU2 WR12 
The cationic amphipathic peptides were designed as demonstrated in helical wheel diagrams. Arginine, 
valine, and tryptophan residues were arranged to form α helices, with the hydrophilic and hydrophobic faces 
indicated in blue and yellow circles, respectively. The 12- and 48-mers LBU1 and WLBU4 are shown as 
representatives of the LBU and WLBU series, respectively. 
 Figure 1 Schematics of WLBU2 and WR12 .[66]
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4.0 RESULTS 
4.1 Defining bacterial concentration by a standard equation for each pathogen 
Light absorbance at different dilutions of bacterial cultures were measured to produce a 
calibration curve which enabled conversion of the optical density (OD) measured into cell counts 
and provided a standard equation for calculating the required concentration. This equation was 
obtained by growing bacteria to the exponential phase as described above, taking OD readings of 
several dilutions, and plating them. Concentration (measured as c.f.u/ml) was plotted against the 
corresponding OD (Figure 2); by performing a linear regression analysis we were able to obtain 
the specific equation for each bacteria (Table 1).  
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(a) F. tularensis (b) B. pseudomallei (c) Y. pestis.  Each OD reading was done in triplicate. A linear regression 
analysis was done using data points collected for each pathogen. 
Figure 2 Calibration curve to calculate the conversion factor between OD reading at 600nm and the 
number of colony forming units growing per ml (c.f.u/ml). 
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Table 1  Equations generated from the calibration curve of each bacteria. 
Bacteria Equation 
F. tularensis Y = 3.774e+009*X - 8.304e+007 
B. Pseudomallei Y = 2.303e+009*X - 3.535e+008 
Y. pestis Y = 8.391e+007*X - 4.056e+006 
Y= bacterial concentration (c.f.u/ml), X = OD 
4.2 In vitro antimicrobial activity of eCAPs 
In order to investigate the antimicrobial activity of WLBU2 and WR12 compared to LL37, 
pathogens were treated with each peptide and evaluated using both a growth inhibition assay and 
a bacterial killing assay. 
4.2.1 Bacterial Killing Assay (BKA) 
The bacterial killing assay, as the name indicates, assesses the potency of each peptide to 
kill the treated bacteria. Pathogens are incubated with 2-fold dilutions of each peptide for 1 hour 
then plated on suitable agar. CFUs are counted to determine the concentration remaining after 
peptide treatment. Figure 3 shows the dose-dependent bacterial reduction of F. tularensis SchuS4 
in percentage after peptide treatment. Both WLBU2 and WR12 outperformed LL37 against 
SchuS4. WLBU2 attained 95% killing at a concentration of 3μM and 85% killing was achieved 
using 100 μM of WR12 (Table 2). The minimum bactericidal concentration (MBC), defined as the 
peptide concentration needed to kill 99% of the bacteria, was not achieved with any of the peptides. 
Statistical analysis revealed significant differences between WLBU2 and LL37 at concentrations 
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≥1.5μM and between WR12 and LL37 at concentrations ≥25μM (P < 0.0001). Moreover, WLBU2 
had significantly better antimicrobial activity against SchuS4 than WR12 at concentrations ≤50μM 
(P <0.0001). Thus, WLBU2 proved to be the best candidate between the tested peptides against 
SchuS4.  
Next, I used the BKA to assess the antimicrobial activity of WLBU2 and WR12 against B. 
pseudomallei. Figure 4 shows the dose-dependent bacterial reduction in percentage after peptide 
treatment. Results show that WR12 and LL37 were unable to reduce bacterial counts of B. 
pseudomallei, while WLBU2 achieved a mean of 45% killing at 100µM (Figure 4A, Table3). 
Although statistical analysis indicates a significant increase in antimicrobial activity for WLBU2 
compared to LL37, a 45% reduction in bacterial count is considered a modest activity. 
In a study done by Kanthawong et al (2009) using potassium phosphate buffer (PPB) rather 
than PBS in the BKA, LL37 achieved 75% - 100% killing of 22 out of 24 different isolates of B. 
pseudomallei [70]. Therefore, I repeated the BKA of B. pseudomallei using PPB as my media. As 
Figure 4B indicates, LL37 and WR12 failed to reduce bacterial counts as before but WLBU2 
activity increased to 60% killing at 25µM. 
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Bacterial cultures (2x106 c.f.u/ml) grown in BHI were treated with two-fold dilutions of the peptide in 
PBS. Percent reduction in bacterial count (y axis) upon treatment is plotted as a function of peptide 
concentration (x axis). Two-way analysis of variance (ANOVA) indicated a (*) significant difference 
at concentration ≥ 1.5μM, p <0.0001 between WLBU and LL37, a (**) significant difference at 
concentration ≥ 25μM, p < 0.0001 between WR12 and LL37, and a (***) significant difference at 
concentration ≤ 50μM, p < 0.0001 between WLBU2 and WR12. The data shown is a result of two 
independent experimental trials. 
 Figure 3 Dose-dependent killing of F. tularensis by WLBU2, WR12 or LL37. 
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Table 2 Percentage killing of F. tularensis by WLBU2, WR12 or LL37. 
Peptide concentrations are summarized according to their ability to achieve 85, 95 and 99% killing of the bacteria. 
Having demonstrated the activity of WLBU2 and WR12 against F. tularensis and B. 
pseudomallei, activity against Y. pestis was assessed. Figure 5 shows a dose-dependent reduction 
of Y. pestis after peptide treatment. Both WLBU2 & WR12 were significantly more effective at 
killing Y. pestis than LL37 with a 95% reduction in bacterial count at a concentration of 25µM of 
WR12 and 100µM of WLBU2 (Table 4). Statistical analysis revealed significant difference 
between WLBU2 and LL37 at concentrations ≥3μM and between WR12 and LL37 at 
concentrations ≥1.5μM (P < 0.0001). No significant difference between WLBU2 and WR12 was 
found against Y. pestis although, WR12 was able to achieve an MBC at a concentration of 50 μM. 
In agreement with the results shown here, a study done by O’Loughlin et al (2010) found that 
LL37 had minimal antimicrobial effect on Y. pestis due to bacterial modification of the outer 
membrane lipids decreasing its net negative charge [71]. 
For the following experiments with F. tularensis BHI medium was substituted with 
Chamberlain’s Chemically Defined Medium (CCDM) due to unexpected difficulties with bacterial 
overnight growth in BHI. Previously, incubation of bacteria for 17 – 19 hours in BHI puts the 
bacterial growth in the exponential phase confirmed by an OD reading of 0.9 – 1 at 600mm. But 
since December 2013, F. tularensis stopped growing at the previous rate reaching a maximum OD 
Francisella tularensis 
%killing WLBU2 (µM) WR12 (µM) LL37 (µM) 
85% < 1.5 100 > 100 
90% 3 > 100 >100 
95% >3 > 100 > 100 
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of 0.5 after 19 hours incubation. Several attempts to restore the previous growth seen in BHI were 
made but were unsuccessful. These included: BHI from different vendors, confirming pH using 
different pH meters and test papers, alternative sources of distilled water, adding cysteine, ferric 
pyrophosphate, or Isovitalex (supplements typically used in other media that supports Francisella 
growth). Growth in CCDM was not altered. Therefore, CCDM replaced the BHI as the media used 
for the overnight culture of F. tularensis. 
Looking back at Figure 3, within the range of WLBU2 doses tested against F. tularensis it 
did not achieve the MBC. A likely explanation was saturation of the peptide required additional 
peptide to achieve the MBC. Figure 6 shows the comparison between the dose-dependent bacterial 
reduction in percentage after WLBU2 treatment with one and two doses. Rather than plating after 
1 hour of incubating the bacteria with the peptide, a second dose of peptide at the same 
concentration tested was added and the plate was incubated for another hour. Clearly, multiple 
dosing of WLBU2 achieved significantly better antimicrobial activity with an MBC of 50 µM 
(Table 5). 
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Bacterial culture (1.2x106 c.f.u/ml) grown in BHI were treated with two-fold dilutions of the peptide in A. 
PBS or B. PPB. Percent reduction in bacterial count (y axis) upon treatment is plotted as a function of 
peptide concentration (x axis). Two-way analysis of variance (ANOVA) of WLBU2 (PBS) versus LL37 (*) 
and WLBU2 (PPB) versus LL37 (**) was performed. (*) significant difference at concentration 25, 50 and 
100μM, p <0.0001. (**) significant difference at concentration ≥ 3μM, p < 0.0001. The data shown is a 
result of three independent experimental trials. 
Figure 4 Dose-dependent killing of B. pseudomallei by WLBU2, WR12 or LL37. 
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Table 3 Percentage killing of B. pseudomallei by WLBU2, WR12 or LL37. 
Peptide concentrations are summarized according to their ability to achieve 85, 95 and 99% killing of the 
bacteria  
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Bacterial cultures (2x106 c.f.u/ml) grown in BHI were treated with two-fold dilutions of the peptide in PBS. 
Percent reduction in bacterial count (y-axis) upon treatment is plotted as a function of peptide concentration 
(x axis). Two-way analysis of variance (ANOVA) of WR12 versus LL37 (*) and WLBU2 versus LL37 (**) 
was performed. (*) significant difference at concentration ≥ 3μM, P < 0.0001. (**) significant difference at 
concentration ≥ 1.5μM, P < 0.0001.  The data shown is a result of three independent experimental trials.
Figure 5 Dose-dependent killing of Y. pestis by WLBU2, WR12 or LL37.
B. pseudomallei 
%killing WLBU2 (µM) WR12 (µM) LL37 (µM) 
85% >100 >100 >100 
90% >100 >100 >100 
95% >100 >100 >100 
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Table 4 Percentage killing of Y. pestis by WLBU2, WR12 or LL37. 
Peptide concentrations are summarized according to their ability to achieve 85, 95 and 99% killing of the bacteria 
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Bacterial cultures (1x106 c.f.u/ml) grown in CCDM were treated with two-fold dilutions of the peptide in 
PBS. Percent reduction in bacterial count (y-axis) upon treatment is plotted as a function of peptide 
concentration (x axis). Two-way analysis of variance (ANOVA) of WLBU2 (one dose) versus WLBU2 
(two doses) was performed. (*) significant difference at concentrations 3, 6.25 and 12.5μM, P < 0.0001. 
The data shown is a result of three independent experimental trials. 
Figure 6 Dose-dependent killing of F. tularensis by one dose and two doses of WLBU2. 
Y. pestis 
%killing WLBU2 (µM) WR12 (µM) LL37 (µM) 
85% 6.25 < 12.5 > 100 
90% <100 < 25 >100 
95% 100 25 > 100 
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Table 5 Percentage killing of F. tularensis by one or two consecutive doses of WLBU2. 
 Francisella tularensis 
%killing 
WLBU2 (µM) 
 One Doses 
WLBU2 (µM) 
   Two Doses 
85% 25 < 3 
90% 50 6 
100% > 100 50 
Peptide concentrations are summarized according to their ability to achieve 85, 90 and 99% killing of the 
bacteria 
4.2.2 Growth inhibition assay (GIA) 
The growth inhibition assay is an in vitro test that depends on the measurement of turbidity 
as an indicator of microorganism population. Deslouches et al demonstrated the usefulness of this 
assay in studying the antimicrobial effects of several peptides on P. aeruginosa and MRSA [66]. 
Using this assay, bacterial growth is monitored after addition of the peptides in growth media with 
the bacteria for 24hr giving us an indication as to their antimicrobial activity. Therefore, in the 
effort to properly evaluate the antimicrobial effect of WLBU2 and WR12 on all three pathogens, 
a growth inhibition assay was performed. 
Figure 7 shows the dose dependent inhibition of F. tularensis growth by WLBU2, WR12 
and LL37. As predicted, WLBU2 had the highest growth inhibition with a minimum inhibitory 
concentration (MIC) of 25 μM (Table 6). WR12 had moderate activity at concentrations ≥12.5µM 
but failed to reach MIC at the highest dose tested (100 μM). WLBU2 had significantly higher 
activity than WR12 between 3 μM and 50μM (P<0.0001). On the other hand, LL37 performed 
better compared to the results obtained in the BKA with a MIC of 50 µM. The difference between 
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the BKA and GIA might be a result of the difference in the liquid media (PBS for the BKA; BHI 
for the GIA) between the two in vitro assays. As mentioned before, in a GIA bacteria are incubated 
with the peptides in a growth medium rather than PBS. Certain components in the BHI might 
enhance the activity of LL37 against F. tularensis. Another explanation could be that the bacteria 
in this assay are incubated with the peptides for 24hr compared to 1 hour in a BKA. Although 
studies have shown that antimicrobial peptides rapidly kill P. aeruginosa within 30 – 180 seconds 
[65], a kinetic analysis of WLBU2, WR12 and LL37 specifically against F. tularensis is needed. 
Further, in the BKA assay the peptide is interacting with static bacteria in comparison to the 
metabolically active bacteria in culture media in the GIA assay.  The difference in bacterial 
membrane dynamics and its stability between the two assays could also justify the variable LL37 
results. 
Figure 8 shows the dose – dependent inhibition of B. pseudomallei growth by WLBU2, 
WR12 or LL37. Similar to the BKA results, none of the peptides were able to achieve their MIC 
within the concentrations tested (Table 7).  LL37 activity is enhanced, as seen before with F. 
tularensis, and a moderate increase in WR12 activity is seen as well. Statistical analysis indicates 
no difference in activity between the three peptides. All were able to reach approximately a 50% 
reduction in growth at the highest concentration tested. 
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 Bacterial cultures (2X106 c.f.u/ml) grown and treated in BHI with twofold dilutions of the peptide. Percent 
inhibition in bacterial growth (y-axis) upon treatment is plotted as a function of peptide concentration (x 
axis). Two-way analysis of variance (ANOVA) of WR12 versus WLBU2 (*), WLBU2 versus LL37 and 
WR12 versus LL37 (**) was performed. (*)(**) significant difference at concentrations between 3 μM and 
50μM, P < 0.0001.  The data shown was a result of three independent experimental trials. Each trial was 
done in triplicates. 
 Figure 7 Dose – dependent inhibition of F. tularensis growth by WLBU2, WR12 or LL37.
Table 6 Percentage inhibition of F. tularensis by WLBU2, WR12 or LL37. 
Peptide concentrations are summarized according to their ability to achieve 85, 95 and 99% inhibition of 
the bacterial growth. 
Francisella tularensis 
%Inhibition WLBU2 (µM) WR12 (µM) LL37 (µM) 
85% <25 >100 25 
90% 25 >100 50 
95% <100 >100 >100 
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The WLBU series of peptides is composed of peptides with the same composition but in 
different lengths. Deslouches et al studied the optimal length and concluded that WLBU2 with 
its 24 residues was the lead compound against P. aeruginosa and MRSA [63]. Due to the 
modest activity of WLBU2 against B. Pseudomallei, the longer peptides WLBU3 & WLBU4 
were tested using the growth inhibition assay. 
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 Bacterial cultures (1.2X106 c.f.u/ml) grown and treated in BHI with two-fold dilutions of the peptide. 
Percent inhibition in bacterial growth (y-axis) upon treatment is plotted as a function of peptide 
concentration (x axis). Two-way analysis of variance (ANOVA) of WR12 versus WLBU2, WLBU2 versus 
LL37 and WR12 versus LL37 was performed. No statistical difference was found. The data shown was 
a result of three independent experimental trials. Each trial was done in triplicates.
Figure 8 Dose – dependent inhibition of B. pseudomallei growth by WLBU2, WR12 or LL37.
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Table 7 Percentage inhibition of B. pseudomallei by WLBU2, WR12 or LL37. 
Peptide concentrations are summarized according to their ability to achieve 85, 95 and 99% inhibition of the 
bacterial growth. 
Figure 9 shows the dose dependent growth inhibition in percentage after treatment with 
each peptide. There was a slight difference between the growth inhibition of the three WLBU 
peptides with WLBU2 and WLBU3 having a significant increase of activity compared to either 
LL37 or WLBU4 at concentration 1.5µM. No significant difference was found between WLBU2 
and WLBU3, thus increasing the length of the peptides did not improve activity against B. 
pseudomallei.  
As for Y. pestis, Figure 10 shows the dose-dependent inhibition of growth by WLBU2, 
WR12 or LL37. Contrary to the results obtained from the BKA, none of the peptides were able to 
achieve MIC, and there were no significant differences between them (Table 8). Again that might 
be due to the effect of the media used for overnight growth on the peptides’ antimicrobial activity 
or bacterial surface composition. 
B. pseudomallei 
%Inhibition WLBU2 (µM) WR12 (µM) LL37 (µM) 
85% >100 >100 >100 
90% >100 >100 >100 
95% >100 >100 >100 
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Bacterial cultures (1.2X106 c.f.u/ml) grown and treated in BHI with twofold dilutions of the peptide. Percent 
inhibition in growth (y-axis) upon treatment is plotted as a function of peptide concentration (x axis). Two-
way analysis of variance (ANOVA) between WLBU2, WLBU3, WLBU4 and LL37 was performed. (*) 
Indicates Statistical difference between WLBU2 and WLBU4, WLBU2 and LL37 at 1.5µM. (**) indicates 
statistical difference between WLBU3 and LL37, WLBU3 and WLBU4 at 1.5µM. The data shown was a 
result of three independent experimental trials. Each trial was done in triplicates.
Figure 9 Dose – dependent inhibition of B. pseudomallei growth by WLBU2, WLBU3, WLBU4 or 
LL37. 
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Bacterial cultures (2X106 c.f.u/ml) grown and treated in Bacto nutrient media with twofold dilutions of the 
peptide. Percent inhibition in bacterial growth (y-axis) upon treatment is plotted as a function of peptide 
concentration (x axis). Two-way analysis of variance (ANOVA) of WR12 versus WLBU2, WLBU2 versus 
LL37 and WR12 versus LL37 was performed. No statistical difference was found. The data shown was a 
result of two independent experimental trials. Each trial was done in triplicates.
Figure 10 Dose – dependent inhibition of Y. pestis growth by WLBU2, WR12 or LL37. 
Table 8 Percentage inhibition of Y. pestis by WLBU2, WR12 or LL37. 
Peptide concentrations are summarized according to their ability to achieve 85, 95 and 99% inhibition of the 
bacterial growth. 
Y. pestis 
%Inhibition WLBU2 (µM) WR12 (µM) LL37 (µM) 
85% >100 >100 >100 
90% >100 >100 >100 
95% >100 >100 >100 
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4.3 Antimicrobial activity of WLBU2 against F. tularensis infected macrophages
Many CAPs act directly by permeabilizing the membrane of the microbial targets without 
interacting with any specific receptors. Thus, their effect on mammalian cells is a concern 
considering that some peptides have shown potentially harmful side effects such as lysis of red 
blood cells [72]. For the ex vivo experiments with eCAPs, a transformed mouse macrophage cell 
line (J774) was infected with F. tularensis. Transformed cells are more sensitive to membrane-
permeabilizing peptides due to higher phospatidylserine content[73]. Before moving on with the 
ex vivo experiments the cytotoxicity of WLBU2 on J774 macrophages was determined using a 
MTS test. As Figure 11 demonstrates WLBU2 treatment resulted in a dose-dependent decrease in 
cell viability with 50% of the cells lost at a concentration of 25μM. Therefore, only WLBU2 
concentrations of 25μM or less were used in any ex vivo experiments. 
F. tularensis is a facultative intracellular organism that invades and multiplies within 
macrophages [74, 75]. Thus, for a treatment to be successful it will have to act on the intracellular 
pathogen. To determine the intracellular antimicrobial effect of WLBU2, ex vivo bacterial 
clearance of SchuS4 from infected macrophage cells (J774) was assessed using concentrations 
ranging from 3μM to 25μM. J774 cells were infected with SchuS4 at an MOI of 1:100, washed, 
and then treated with different concentrations of WLBU2 (3µM to 25µM) for one hour. Cell lysate 
was plated on CHA plates to determine bacterial killing and bacterial colonies were counted after 
48 hours of incubation. Figure 12 illustrates the dose-dependent killing of intracellular F. 
tularensis by WLBU2. WLBU2 demonstrated a high antimicrobial efficacy against intracellular 
bacteria with only 20% bacteria remaining after treatment with 12.5μM for an hour. These findings 
combined with the MTS test results suggest that at a dose of 12.5 μM the peptide is able to kill 
most of the intracellular bacteria with minimal harm to the mammalian cells. 
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Cell viability was determined using a MTS assay. Treatment of cells with WLBU2 resulted in a dose-
dependent decrease in cell viability with 50% of the cells lost at a concentration of 25μM. Results of cell 
growth was measured relative to a control where J774 cells were grown in 100% media. The data shown 
was a result of three independent experimental trials. 
Figure 11 J774 macrophage cells treated for 1 hour with a range of concentrations of WLBU2. 
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F. tularensis infected J774 cells (MOI 1:100) were treated with twofold dilutions of WLBU2 for 1 hour. 
Percent remaining of the bacteria (y-axis) upon treatment is plotted as a function of peptide concentration 
(x axis). The data shown was a result of three independent experimental trials. 
 Figure 12 Dose-dependent killing of intracellular F. tularensis by WLBU2.
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5.0 DISCUSSION 
The discovery of numerous natural cationic peptides in the last three decades and their 
antimicrobial role in our bodies has sparked the interest of many scientists. The growing 
understanding of the structure and function of such peptides led to the development of several 
eCAPs such as WLBU and WR series. Here the antimicrobial activity of WLBU and WR12 
peptides was tested against three tier 1 select agents: Francisella tularensis, Burkholderia 
pseudomallei and Yersinia pestis. These bacterial agents are considered tier 1 agents due to their 
potential for misuse, high fatality rate if not treated appropriately, and the development of 
antibiotic resistance to their current effective treatment. 
Previous studies documented the superior antimicrobial activity of WLBU2 and WR12 
against several bacterial agents such as P. aeruginosa and MRSA [65-68]. In this study, in vitro 
tests of WLBU2 and WR12 also demonstrated superior antimicrobial effect against F. tularensis 
and Y. pestis when compared to the natural peptide (LL37).  WLBU2 proved to be the best 
candidate against F. tularensis with a single dose of 3μM needed to achieve a 90% reduction in 
bacterial count and a MIC of 25 μM. Both WLBU2 and WR12 achieved similar results against Y. 
pestis, but only WR12 was able to attain a MBC of 50 μM. 
B. pseudomallei provided a greater challenge with only moderate susceptibility to WLBU2. 
Nevertheless, WLBU2 antimicrobial effectiveness against B. pseudomallei surpasses that of LL37. 
It was also observed that results depended on the testing environment. A substantial reduction in 
bacterial count was seen with WLBU2 in potassium phosphate buffer but not in phosphate buffered 
saline. The role of PPB in enhancing the peptides’ antimicrobial function is still unclear. PPB may 
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affect the bacterial membrane enhancing its disruption by the peptide or create a more suitable 
environment for peptide activity. The difference in outcome between my experiments and the 
Kanthawong et al study concerning LL37 might be related to the B. pseudomallei isolates used. 
The isolate used in this study, 1026b, is considered a “prototypical” lab strain isolated from a 
diabetic 29-year-old female patient with septicemic melioidosis. While in Kanthawong et al, 13 
isolates were from patients admitted to Srinagarind Hospital (Faculty of Medicine, Khon Kaen 
University, Khon Kaen, Thailand), and the other 11 were from soil collected from the northeastern 
endemic region of Thailand [70]. It is well established that there are different LPS structures of B. 
pseudomallei depending on the isolate: smooth type A, smooth type B, rough type A or rough type 
B LPS structures [76]. Since LPS form a major part of the outer membrane of the bacteria and 
shields it from antimicrobial attacks, such variation might contribute to the variation in bacterial 
susceptibility to peptides [77]. Additional complexity to bacterial surfaces is generated by 
production of surface polysaccharide capsules. Bacterial capsule is known to hinder complement 
activation and phagocytosis of B. pseudomallei [78]. Wikraiphat et al further showed that capsule 
mutants of this bacterium survived poorly in macrophages and were more susceptible to 
antimicrobial killing  by histatin and lactoferrin when compared to the wild type [79]. Also, 
Hayden et al suggested that genetic changes that occur in subpopulations of B. pseudomallei during 
acute infections and post-treatment are not found in 1026b which could contribute to the variance 
seen in the antimicrobial activity of the peptides [80]. 
The mechanism of action of these peptides is still under investigation but the general 
assumption is that their antimicrobial action stems from their ability to attach and disrupt the 
microbial outer membrane leading to depolarization, metabolite leakage, and ultimately death of 
the pathogen (Figure 13). The variability of surface-exposed structures on the outer membrane and 
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capsule of the three pathogens in this study may explain the difference in the antimicrobial activity 
of the eCAPs. Several studies verified the influence of certain antigens found on the surface of Y. 
pestis and F. tularensis in increasing their susceptibility to certain CAPs. For example, Galvan et 
al demonstrated that the susceptibility of Y. pestis to CAPs such as cathelicidin is mediated by the 
capsular antigen fraction 1 [81].  Also, Vonkavaara et al illustrated the importance of surface lipid 
A and Kdo core for interactions of F. tularensis with CAPs. On the other hand, Madhongsa et al 
demonstrated that the MIC value of  several peptides such as polymyxin B for B. pseudomallei is 
several magnitudes higher than those of P. aeruginosa or E. coli due to the type of  LPS moiety 
on its outer membrane [76]. Further, B. pseudomallei resists treatment by forming micro-colonies 
using its glycol-calyx polysaccharide capsule and creating a protective environment against the 
peptide. This might explain eCAPs enhanced activity against F. tularensis and Y. pestis in 
comparison to the moderate antimicrobial effect of WLBU2 and failure of WR12 against B. 
pseudomallei. 
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In this model the attached peptides aggregate and inser into the bacterial membrane so that hydrophobic 
peptide regions align with the lipid core region and the hydrophilic peptide region form the interior 
region of the pore. Hydrophilic regions of the peptide are shown coloured red, hydrophobic regions of 
the peptide are shown coloure blue. Reprinted by permission from Macmillan Publishers Ltd: Nature 
[82], copyright 2005. 
Figure 13 A model of antimicrobial peptides mechanism of action.
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It important to note that the antimicrobial activity of WLBU2 was affected by the media 
used in overnight cultures of bacteria. F. tularensis grown in BHI was more susceptible to WLBU2 
with 90% reduction at 3µM compared to 50 µM for the bacteria grown in CCDM. Hazlett et al 
have shown that SDS-PAGE analysis of F. tularensis grown in CCDM or Muller Hinton Broth 
(MHB) displayed different protein profiles from those grown in BHI. While F. tularensis grown 
in BHI had similar mRNA profile to the bacteria isolated from macrophages, MHB and CCDM 
yield bacteria that are phenotypically different with abundant outer membrane proteins that are 
usually down-regulated during host adaptation [83]. This difference might be due to the high level 
of free amino acids in MHB (120 mM) and CCDM (75mM) affecting the protein production in 
bacteria. Further, Cherwonogrodzkey et al demonstrated that when encapsulated LVS was 
passaged in CCDM it created a thicker capsule and increases in virulence [84]. Because CAPs 
interact with bacterial surface, variation in the outer membrane proteins and capsule production by 
different media might be responsible for the difference in WLBU2 activity against F. tularensis.      
In practice, antibiotics are usually given in multiple doses to maintain a drug concentration 
capable of ridding the infected body from the pathogens. When a single dose of WLBU2 was 
tested against F. tularensis, it was unable to achieve a MBC and leveled off at 97% reduction in 
bacterial count. We theorized that saturation of WLBU2 was accounting for the inability of 
WLBU2 to achieve the MBC (defined as ≥99% killing). With that in mind, WLBU2 was tested in 
vitro with 2 consecutive doses at the same concentration. Compared to a single dose, WLBU2 
multiple dosing proved to be more effective with complete killing of F. tularensis at 50 μM 
(MBC=50 μM). Basically, the initial dose of 50 µM WLBU2 eliminated more than 90% of the 
bacteria making it easier for the second dose to achieve complete killing. Also, WLBU2 multiple 
dosing performed better than the single dosing over the whole gradient of doses. This further 
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confirms the assumption that saturation of the peptide had occurred, requiring additional peptide 
to achieve higher killing activity and that bacteria surviving the first dose of peptide were not 
resistant to WLBU2. 
During the generation of the WLBU series, peptides were tested against P. aeruginosa to 
determine the length for optimal antimicrobial activity. It was thought that longer peptides would 
have higher activity due to their greater membrane-spanning capacity. Nevertheless, WLBU2 with 
its 24 residues had the ideal length against P. aeruginosa with no noticeable increase in activity 
with WLBU3 (36-residue) and WLBU4 (48-residue) [63]. Similarly, when testing WLBU2, 3 and 
4 against B. pseudomallei there were no noticeable difference in the growth inhibition of the three 
peptides against this pathogen. Thus, B. pseudomallei is able to resist the antimicrobial effect of 
the WLBU series regardless of their length. Madhongsa et al emphasized the structure activity 
relationship of the antimicrobial peptides and its importance against B. pseudomallei. Using an 
isolate with high biofilm production (H777), Madhongsa et al demonstrated the higher efficacy of 
cyclic bacitracin against B. pseudomallei compared to other linear αhelix peptides [76]. Therefore, 
greater membrane permeabilization ability against our tested isolate might be achieved not by 
increasing the length of the our peptides but by higher order of oligomers and cyclic structures
In light of the evident antibacterial efficacy of WLBU2 in vitro, it is vital to know whether 
this peptide displays any toxicity to mammalian cells or not. Deslouches et al demonstrated that 
concentrations up to 30μM of WLBU2 can damage the bacterial cells while sparing leukocytes 
and human skin fibroblasts [64]. This antimicrobial selectivity may be attributed to the difference 
in lipid content between eukaryotic and bacterial cell membranes. Due to the presence of 
cholesterol in eukaryotic membranes they tend to form weaker hydrophobic interactions with 
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eCAPs, while the negatively charged bacterial membranes forms a strong electrostatic interaction 
with the them [85]. 
F. tularensis is an intracellular organism that invades and replicates in macrophages. 
Accordingly, for the peptides to be effective in vivo they would have to exert their antimicrobial 
activity on intracellular pathogens with minimal effect on the macrophages. From the MTS 
staining assays results it was concluded that while WLBU2 could be toxic for J774 cells, under 
the concentration of 25μM WLBU2 had minimal toxic effect on J774 macrophages. Taking that 
into consideration, all ex vivo infected macrophages were treated with concentrations of less than 
25μM of WLBU2. WLBU2 demonstrated a high antimicrobial efficacy against intracellular 
bacteria with only 20% bacteria remaining after treatment with 12.5μM for an hour. Despite our 
limited knowledge about the pharmacokinetics and dynamics of these peptides, results of the ex 
vivo experiments using WLBU2 against F. tularensis infected macrophages suggest that the 
peptide is able to kill the intracullar bacteria with minimal harm to the mammalian cells. 
Several factors should be considered when these peptides are tested in in vivo settings, 
including the concentrations of antimicrobial peptides at the sites of infection, inhibiting or 
synergistic substances present in tissues and fluids (i.e. lysozyme, natural antimicrobial peptides 
and physiological salt concentrations). Deslouches et al demonstrated that the WLBU2 had 
prophylactic and therapeutic effects against P. aeruginosa bacteraemia in mice; 3 and 4 mg/kg 
given 1 hour post-infection was able to increase survival rates compared to control [65]. Therefore, 
for future directions I would suggest assessing the antimicrobial activity and toxicity of WLBU2 
in a mouse model for tularemia. Balb/c mice can be infected via the respiratory tract by aerosol 
delivery of SchuS4 and then treated with i.v. (intravenous) or i.n. (intranasal) WLBU2. Mice 
weight and temperature should be monitored daily to evaluate the effectiveness of WLBU2 in 
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clearing the infection. Also the same model can be used to assess the benefits of prophylactic and 
multiple dosing of the peptide. 
In conclusion, there are three major requirements for any successful antimicrobial peptides: 
potency, specificity and activity under physiological conditions. In this study we demonstrated the 
potency of WLBU2 and its selectivity for F. tularensis. Further investigation is warranted, but 
WLBU2 demonstrates a great potential as a broad spectrum antimicrobial agent against F. 
tularensis. As for B. pseudomallei and Y. pestis, results were inconclusive about the usefulness of 
WLBU and WR12 against these pathogens. Nevertheless, eCAPs could be useful as a broad-
spectrum countermeasure in situations concerning public health, such as bioterror attacks, until the 
causative agent is identified.    
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